Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7738685 | 0.74 | NUDT1 (0.31) | — | |
| SCHEMBL30439125 | 0.59 | MAPK1 (0.44) | MAPK1AXL | |
| SCHEMBL1126077 | 0.59 | MAPK1 (0.44) | MAPK1AXL | |
| SCHEMBL12413071 | 0.58 | MGAM (0.38) | AXL | |
| SCHEMBL21224338 | 0.58 | BRD4 (0.36) | MAPK1 | |
| SCHEMBL2628389 | 0.56 | ADORA2A (0.37) | — | |
| SCHEMBL352077 | 0.56 | HSP90AA1 (0.39) | MAPK1 | |
| SCHEMBL29360166 | 0.56 | HSP90AA1 (0.39) | MAPK1 | |
| SCHEMBL29385656 | 0.56 | HSP90AA1 (0.39) | MAPK1 | |
| SCHEMBL30358616 | 0.56 | HSP90AA1 (0.39) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119637-B2 | Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119637-B2 | Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8110576-B2 | Pyrrolo(2,3-b)pyrazine compounds; Raf kinase inhibitors including A-Raf, B-Raf and/or c-Raf-1 oncogenes; melanoma, colorectal cancer, thyroid cancer, ovarian cancer, cholangiocarcinoma, pain or polycystic kidney disease | PLEXXIKON INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110576-B2 | Pyrrolo(2,3-b)pyrazine compounds; Raf kinase inhibitors including A-Raf, B-Raf and/or c-Raf-1 oncogenes; melanoma, colorectal cancer, thyroid cancer, ovarian cancer, cholangiocarcinoma, pain or polycystic kidney disease | PLEXXIKON INC. (US) | 2012-02-07 | — | — | US | disclosed |
| WO-2009152083-A1 | 5H-PYRR0L0 [2,3-B] PYRAZINE DERIVATIVES FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009152087-A1 | BICYCLIC HETEROARYL COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090306086-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306087-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306087-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306086-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306087-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, PRKACA, RAF1 | MAPK1 79/4885AXL 219/4885 |
| US-20090306086-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKACA, KIT, FLT3 | MAPK1 143/4885AXL 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.